Research and experimental development on natural sciences and engineering
LYTIX BIOPHARMA ASA
Revenue 2024
NOK 11.1m
Operating profit
NOK −95.9m
Equity
NOK 107.9m
Incorporated
2003
Employees
6
Share capital
NOK 7.7m
Financials
Total operating revenue
Operating profit (EBIT)
Income statement
| Post | 2024 | Trend |
|---|---|---|
| Total operating revenue | 11.1m | |
| Total operating costs | 107.0m | |
| Operating profit (EBIT) | −95.9m | |
| Net financial items | 1.6m | |
| Profit for the year | −94.3m |
Balance sheet
| Post | 2024 | Trend |
|---|---|---|
| Total assets | 146.5m | |
| of which current assets | 143.9m | |
| Equity | 107.9m | |
| Total liabilities | 38.6m |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.